Back to User profile » Ms Lindsay Dozeman
Paper published by Ms Lindsay Dozeman:
Original Research
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma
Nadiminti K, Singh Abbi KK, Mott SL, Dozeman L, Tricot A, Schultz A, Behrends S, Zhan F, Tricot G
OncoTargets and Therapy 2017, 10:217-226
Published Date: 6 January 2017